DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Protonix (Pantoprazole Sodium) - Summary



The active ingredient in PROTONIX® (pantoprazole sodium) Delayed-Release Tablets is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F2N3NaO4S x 1.

PROTONIX® (pantoprazole sodium) Delayed-Release Tablets are indicated for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those patients who have not healed after 8 weeks of treatment, an additional 8 week course of PROTONIX may be considered.

PROTONIX Delayed-Release Tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in patients with gastroesophageal reflux disease (GERD). Controlled studies did not extend beyond 12 months.

PROTONIX Delayed-Release Tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

See all Protonix indications & dosage >>


Published Studies Related to Protonix (Pantoprazole)

Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. [2014]
AIM: To compare the efficacy of pantoprazole-Mg and esomeprazole in GERD... CONCLUSIONS: Pantoprazole-Mg 40 mg was at least as effective as esomeprazole

Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial. [2012]
esophagitis... CONCLUSION: The efficacy and safety of 20 mg S-pantoprazole were comparable to

Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. [2012]
Sevelamer hydrochloride (HCL) is thought to require an appropriately acidic environment in order to bind gastrointestinal phosphate. Changes in gastric acidity with acid suppressants may therefore alter the efficacy of sevelamer HCL... Although our study did not find a significant drug interaction, given the high prevalence of acid suppressant use in dialysis patients, physicians should be aware of the potential influence of acid suppression on the efficacy of phosphate binders and regularly assess the clinical need for acid suppression therapy.

Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. [2011.08.01]
BACKGROUND AND OBJECTIVE: The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD). The studies described in this manuscript were conducted to fulfil the requirements of the paediatric written request for pantoprazole by the US FDA... CONCLUSIONS: Exposure increased with increasing doses of pantoprazole granules, even though wide interindividual variability was observed. Compared with that in adults receiving pantoprazole 40 mg, exposure obtained with the 1.2 mg/kg dose was similar in study 1 and slightly lower in study 2. Pantoprazole was generally well tolerated in infants and children aged 1 month through <6 years with GORD. Trial registration numbers (ClinicalTrials.gov): NCT00259012 (study 1) and NCT00141817 (study 2).

Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. [2011.06]
CONCLUSIONS: Pantoprazole therapy used at high doses is not associated with modulation of the pharmacodynamic effects of clopidogrel, irrespective of timing of drug administration. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01170533.

more studies >>

Clinical Trials Related to Protonix (Pantoprazole)

Intravenous (IV) Pantoprazole in Erosive Esophagitis [Completed]
The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.

Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study [Recruiting]
The World Health Organization has declared childhood obesity to be "one of the most serious public health challenges of the 21st century," (http://www. who. int/dietphysicalactivity/childhood). Given that obese children are generally excluded from clinical trials, little to no information exists regarding the impact of obesity on drug disposition and drug action, creating a gap in physicians' knowledge on how to appropriately select the dose of many critical medications (e. g., anticancer agents), so as to prevent toxicity associated with overdosing, while avoiding the harms of under-treatment. The proposed study will examine the effect of obesity on the metabolism of a commonly used medication, the proton pump inhibitor pantoprazole, by exploring the relationships between age, obesity, basal metabolic rate and genetic control of the enzyme primarily responsible for pantoprazole metabolism. We will also validate a simple breath test that can be used to predict pantoprazole dose requirement for obese children. The study is designed to test the following experimental hypotheses:[13C]-pantoprazole pharmacokinetic parameters are not different between non-obese and obese children and adolescents, collectively (both age groups combined) or stratified by age group (SA 1) [13C]-pantoprazole pharmacokinetic parameters or DOB values (and thus, CYP2C19 activity) are not different between males and females (SA 1 & 2) [13C]-pantoprazole pharmacokinetic parameters and DOB (Delta over baseline) values (and thus, CYP2C19 activity) are independent of age over the age range of 6 to 17 years (SA 1 & 2) Obesity does not alter the relative contributions of CYP2C19-dependent and non-CYP2C19-dependent (i. e., CYP3A4) metabolism of pantoprazole, as measured by the urinary ratio of 4-hydroxy-pantoprazole to pantoprazole sulfone (SA 1 & 2) The [13C]-pantoprazole breath test, by determining DOB at discrete time point(s), is a non-invasive measure of CYP2C19 phenotype (SA 2) Clearance of pantoprazole (surrogate for CYP2C19 activity) is a function of REE in obese and non-obese children and adolescents (SA 3) Pantoprazole clearance (surrogate for CYP2C19 activity) is associated with fat distribution, as determined by waist-to-hip ratios (SA 3)

Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets [Completed]
The objective of this study was to determine the single-dose bioequivalence of the test product, a potential generic 40 mg pantoprazole delayed-release tablet formulation, compared with the reference product, a pantoprazole 40 mg delayed-release tablet formulation (Protonix, Wyeth Pharmaceuticals), following a single dose in the fasted state.

Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours [Completed]
This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been identified, six additional patients with metastatic solid tumours will be treated at the RP2D to confirm its tolerability.

Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications [Enrolling by invitation]
The purpose of this 9-day study is to determine if: 1. Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i. e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) 2. Serum gastrin levels change within a week of starting or stopping pantoprazole

more trials >>

Reports of Suspected Protonix (Pantoprazole) Side Effects

Malaise (104)Drug Ineffective (92)Cerebrovascular Accident (70)Nausea (54)Gastrooesophageal Reflux Disease (53)Pain (45)Myocardial Infarction (43)Gastric Disorder (40)Hypertension (40)Death (39)more >>


Based on a total of 19 ratings/reviews, Protonix has an overall score of 8.21. The effectiveness score is 8.42 and the side effect score is 9.16. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Protonix review by 52 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   GERD
Dosage & duration:   40mg taken once a day for the period of 3 months
Other conditions:   hypertension, ulcer
Other drugs taken:   Diovan HCT, Altace
Reported Results
Benefits:   Within two days, the severe burning pain of the GERD disappeared. At three months of treatment, the pain from the ulcer has receded considerably. Because of the ulcer, however, I still have to be careful not to eat anything too acidic--very fresh pasta sauce with chunks of tomato--or too spicy.
Side effects:   Shortly after starting treatment, I developed diarrhea. It only lasted for a few days, but then I continue to have somewhat pasty stools, with occasional bouts of diarrhea again.
Comments:   I went to the ER with severe burning in the chest. The doctors there suspected either cardiac problems or a blood clot in the lungs. Once they made certain there were no blood clots, and that the EKG and cardiac enzyme levels were normal, they started me on IV protonix. The next day I was switched to pill form of the protonix, and the improvement was amazing. Within thirty-six hours the pain was minimal, and by the third day of treatment, it was virtually gone. Since then, I haven't had any recurrence, and remain on the protonix only because of the ulcer, which is improving, even though at a slower pace. Overall, it's an excellent medication, and had worked wonders for me.


Protonix review by 29 year old male patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   Functional Dyspepsia
Dosage & duration:   40mg, once daily. taken once per day for the period of Four months, so far
Other conditions:   IBS
Other drugs taken:   Domperidone (for nausea/bloating)
Reported Results
Benefits:   I have/had an extremely easy to irritate stomach, over-sensitive to acid and food consumption. I spent most days feeling unbelievably bloated, even after only a few bites of food, sometimes. Protonix was prescribed to me in combination with Domperidone to reduce bloating, belching, and an acid-burning sensation in the stomach.
Side effects:   None, really, that I can specifically blame on this drug. I had actually reacted fairly badly to other, similar drugs. The famous "purple pill" Nexium had actually given me a brutal headache, sore-throat, and even a racing heart-beat at times. I was somewhat anxious about taking another very similar medication, but Pantoprazole did not bother me at all (I have since read that Pantoprazole is one of the acid-reducers least likely to cause side-effects).
Comments:   Treatment has been ongoing for several months and is set to continue. While still not quite "normal", I am feeling much better after several months of this therapy and will be discussing reducing my dosage and/or going off the drug completely in the next month or two.


Protonix review by 66 year old female patient

Overall rating:  
Effectiveness:   Ineffective
Side effects:   Extremely Severe Side Effects
Treatment Info
Condition / reason:   gastrointestinal disorder
Dosage & duration:   dont remember (dosage frequency: once daily) for the period of on 2 occasions
Other conditions:   high blood presure
Other drugs taken:   hytrin premerin
Reported Results
Benefits:   none
Side effects:   On the first occasion I took this drug, I experienced mild tingling and redness of my hands and feet and face. I became somewhat week and faint like . I did not, at the time tie these reactions to the medecation. When I took it on a seperate occasion I experienced extreme tingling, redness and diarea and had to be transported to the hospital where they treated me for toxic shock. passed out
Comments:   Benadril, allegra and other intravenious medication I am not sure of.

See all Protonix reviews / ratings >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017